A Smart Investment in Your Health and Happiness
Obesity is a chronic condition, but for the first time, we have tools that can truly change the journey and make you both healthy and happy.
GLP-1 medications like Wegovy®, Ozempic®, and Mounjaro® are not quick fixes. They are a long-term investment in your health, your energy, your confidence, and your future. As we believe at Azento Health, they are "an investment in your Health and Happiness."
As Swiss Re, a leading global reinsurance company, has recently highlighted, when used appropriately, GLP-1 medications can reduce disease, extend life, and significantly improve overall wellbeing, emphasising that “to maximise the benefits, patients must adhere to treatment, manage side effects, and incorporate long-term lifestyle changes. Swiss Re adds that, “if the success of a combined approach works, these drugs have the potential to play a role in the reversal of long-term outcomes of obesity, which have adversely impacted recent mortality trends.” [1]
Let’s explore how to make the most of this opportunity, why this investment is worth it, and how Forte80™ helps you safeguard it.
Breaking Down the GLP-1 Cost and Why the Investment Pays Off
In Switzerland and across Europe, GLP-1 medications cost between CHF/EUR 115–200 per month, depending on the brand and dosage. That is approximately CHF/EUR 4–7 per day. [2] The same or lower as:
- A takeaway coffee or juice.
- A sandwich from a kiosk.
- A short train or tram ticket.
Losing weight, with or without GLP-1 medications, and committing to a healthier lifestyle is a daily journey towards: [3]
- Better health with lower risk of heart attack, stroke, and diabetes.
- Better energy, mood, and sleep.
- A longer, healthier, more active and happier life.
For example, studies on obesity treatment with Wegovy have confirmed a 20% reduction in major cardiovascular events, as demonstrated by the SELECT trial. [4] Furthermore, GLP-1 receptor agonists have been shown to reduce the risk of kidney failure and related complications by 16–19%, even in people without diabetes, according to a meta-analysis of 11 trials with over 85,000 participants. [5]
In short, GLP-1s do not just help you lose weight - they help you live better. And it reduces a lot of cost related to the different co-morbidities.
But Side Effects Can Derail the Journey
Here is the challenge: GLP-1s can trigger digestive side effects, especially in the first few weeks and months. Common issues include:
- Nausea or reflux.
- Constipation.
- Bloating.
- Cramping or digestive sluggishness. [6]
These are not just uncomfortable, they are a leading reason people stop treatment early, missing out on the long-term benefits. They can be discouraging and unwelcome, especially when you are committing to a healthier, more empowered lifestyle.
Final Thought: Health and Happiness Are Worth It
Fighting obesity is not easy. It is hard, but worth the journey. At CHF/Euro 4–7 per day (some places paid by health insurance or reimbursed), GLP-1s are “health spends” that have shown a true return. Because feeling well and support your gut health while you lose weight is not a luxury. It is essential. And you deserve it.
References:
- Weight Loss Injectables: The Boom of GLP-1 Drugs. Swiss Re. 2024.
https://www.swissre.com/reinsurance/insights/weight-loss-injectables.html - Canadian Insulin: Ozempic Price Comparison Reveals Shocking Global Differences. Reuters. 2025.
https://www.reuters.com/press-releases/canadian-insulin-ozempic-price-comparison-reveals-shocking-global-differences-2025-05-16/ - Obesity and Overweight Fact Sheet. WHO. 2024.
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight - Deanfield J., et al. Semaglutide and Cardiovascular Outcomes in Patients with Obesity without Diabetes (SELECT trial). The Lancet. 2024.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01498-3/fulltext - Kristensen SL., et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomized controlled trials. The Lancet Diabetes & Endocrinology. 2025.
https://pubmed.ncbi.nlm.nih.gov/39608381/ - Whitten A., Illuminating the Full Side Effect Profile of GLP-1 Drugs. Drug Discovery News. 2025.
https://www.drugdiscoverynews.com/illuminating-the-full-side-effect-profile-of-glp-1-drugs-16259
